Short answer
Entrada Therapeutics, Inc. (TRDA) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $875,000 (down 95.7% year over year) with net income of −$40M.
Q1 2026 key financials · XBRL
- Revenue
- $875,000
- −95.7% YoY
- Net income
- −$40M
- −128.9% YoY
- Operating margin
- -4834.6%
- EPS (diluted)
- −$0.95
- −126.2% YoY
Source: XBRL data from the Entrada Therapeutics, Inc. (TRDA) Q1 2026 10-Q on SEC EDGAR. USD.
Entrada Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue not provided for quarterly comparison
- Cash, equivalents and marketable securities $254.9M as of March 31, 2026
- Cash runway into Q3 2027 based on current operating plans
- ENTR-601-44 best-performing program with dystrophin increase 2.36% to 6.36% total
- Near-term catalysts: ENTR-601-45 Cohort 1 data mid-2026 and ENTR-601-44 Cohort 2 results by year-end 2026
Risk Factors
- No quarter-specific additions or changes identified in the provided excerpt
- Liquidity risk: cash, equivalents, and marketable securities expected to fund operations into third quarter 2027
- Financing risk: $150.0 million at-the-market offering may not generate proceeds at acceptable prices
- Regulatory risk: FDA may require additional preclinical studies before U.S. clinical-trial commencement
- Development risk: ENTR-601-44 failure could materially diminish the EEV Platform and multiple pipeline programs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Entrada Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.